Cancer Immunotherapy Market Worth $152.83 Billion By 2024
The global cancer immunotherapy
market study presents historical market data in terms of values (2016
and 2017), estimated current data (2018), and forecasts for 2024-by product
(monoclonal antibodies, checkpoint inhibitors, immunomodulators, vaccines, and
cell therapy), application (lung cancer, breast cancer, multiple myeloma,
colorectal cancer, melanoma, prostate cancer, and other cancer types), and end
user (hospitals, and clinics & others). The study also evaluates industry
competitors and analyzes the market at regional and country level.
 |
| Cancer Immunotherapy Market |
On the basis of product type, monoclonal
antibodies segment commanded the largest share of the global cancer
immunotherapy market in 2017. However, checkpoint inhibitors market is expected
to grow at the fastest CAGR during the forecast period, owing to high success
rate of PD-1 & PD-L1 drugs and increasing pipelines of biotechnology and
pharmaceutical companies with combination therapies for anti-PD-1 and PD-L1
inhibitors. Moreover, cell therapy market is also expected to witness
significant growth through 2024. Development of new and effective therapy
options to cure symptoms of the disease is a key factor contributing to growth
of cell therapy market.
On the basis of application, cancer
immunotherapy market for lung cancer application commanded the largest share of
the global market in 2017. Major factors propelling the growth of cancer
immunotherapy market in lung cancer application are growing incidence,
mortality rate, and benefits of immunotherapy to the lung cancer patients;
whereas, cancer immunotherapy market for multiple myeloma applications expected
to witness the highest growth rate during the forecast period. The approval of
innovative caner immunotherapy for the treatment of multiple myeloma has
increased the adoption of immunotherapies in treatment of multiple myeloma.
Moreover, recognizing the potential of immunotherapy in multiple myeloma, major
players in immunotherapy market such as Celgene, Amgen, Janssen, and Juno
Therapeutics engaged in multiple collaborations to evaluate certain drug
entities for the treatment of multiple myeloma.
On the basis of end user, hospitals dominated
the global market. This is mainly attributed to the rise in healthcare spending
which has resulted in the increasing use of immunotherapeutic drugs in hospitals
and the large number of patients being treated in hospitals for cancer
immunotherapy; however, clinics and other end user markets are expected to
witness a rapid growth during the forecast period with the increasing number of
clinics providing cancer immunotherapy, and rising number of ongoing clinical
trials for immunotherapy drugs.
Request for a sample of this research report @
- https://www.meticulousresearch.com/download-sample-report/cp_id=4690
This research report analyzes major
geographies and provides comprehensive analysis of North America (U.S.,
Canada), Europe (Germany, France, UK, Italy, Spain, and Rest of Europe),
Asia-Pacific (China, Japan, India, and RoAPAC), Latin America, and Middle East
& Africa. North America commanded the largest share of the global cancer
immunotherapy market in 2017, followed by Europe and Asia Pacific. However,
Asia Pacific region is expected to grow at a higher CAGR during the forecast
period. Growth in this market is expected to be driven by large pool of patient
population seeking the cancer treatment, increasing prevalence of cancer,
aggressive investment by the major players in the market, increasing government
spending on the healthcare, and increasing disposable income of the population
that improved the access to cancer treatment. Furthermore, lack of stringent
regulations and liberalization in Asian countries is also a key factor making
Asia Pacific a lucrative market.
The major players operating in the global
cancer immunotherapy market are F. Hoffmann-La Roche (Switzerland), Celgene
Corporation (US), Bristol-Myers Squibb (US), Merck & Co., Inc. (US), and
Amgen Inc. (US),ELI Lilly and Company (US), Janssen Global Services, LLC (US)
(Johnson and Johnson), Novartis (Switzerland), Pfizer, Inc. (US), Gilead
Sciences, Inc. (US), Dendreon Pharmaceuticals (US), and Bayer (Germany) among
others.
Contact Info:
Khushal
Contact Sales-+91-744-7780008
Comments
Post a Comment